Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Stocktreeon Nov 18, 2021 9:20am
114 Views
Post# 34140020

merdesman is not good at crunching numbers that matter...

merdesman is not good at crunching numbers that matter...
and is even worse about predicting what will happen with Spectral Medical.

Here is another one of his famous insights regarding this company. It is from a conversation et had with BayStreetWild not so far ago, in August. See if you can recognize a pattern with all his posts.

BayStreetWild –
 
“At this enrolment rate the market is pricing in a multi year delay.  20 people in 36 months? Ouch.”
 
merdesman –
 
“Are you suggesting that once it is announced that Kellum has got the enrollment back up to 10+ per month (as implied in recent discussions/releases) that the stock will quickly get re-priced higher?  Especially since that would imply interim data targets (90) being achieved as early as this coming Feb or March - and not a further multi-year delay that you seem to imply is the current market expectation?”
 
BayStreetWild –
 
“It would be nothing short of a miracle for 10+ to be enrolled per month. So far the number is substantially less than 1 per month so it's not even realistic at this point. 
 
When you say Kellum has got it back to 10+ per month, what do you mean? It has never in the history of Tigris been 10 so how would it "go back"? That's quite misleading of you.”
 
merdesman –
 
“I guess I am perhaps somewhat niavely assuming that with a world-renowned Key-Opinion-Leader, now on board, as the CMO, and that with all his first hand knowledge of these US hospitals and presumably some of the Mgrs at each (and the fact that many new locations were hand picked by him) that each hospital can somehow get to a little under one patient per month (on average). 10/15 = .667 patients per hospital per month (in order to average 10 patients per month across 15 hospitals).”

He likes to take you on a "facts" journey, but it is just his sleasy used car salesman way of earning his salary on the Stockhouse text exchange.

<< Previous
Bullboard Posts
Next >>